Penn’s gene therapy program has signed a 150,000 sq ft lease at a former GlaxoSmithKline property in King of Prussia

“The Penn transaction is an indicator that the entire region is benefiting from the research being done in our world-renowned institutions.”

“Dr. Wilson and his incredible team at Penn have helped establish Philadelphia as a leader in gene therapies,” he said. “We are deeply honored to have the opportunity to work with him and his incredible team of scientists through the expansion of their world-class research and development labs.”

Read More in the Philadelphia Inquirer

Skip to content